Levothyroxine: A black swan? [BE/BA News]
There isn't any biological background that might explain this issue? Or problems during manufacturing? This is really awkward... the CI and point estimate are far more "perfect" than I am used to see. In fact, in full replicate studies, I've seen reference drugs "performing" poorly when compared with single administrations of themselves... Is the dose-toxicity so sensible for this drug that event the narrower limits does not apply in this case? Did a quick search and haven't find any study reporting the dose-response of this drug
Complete thread:
- Levothyroxine: A black swan? Helmut 2017-11-26 12:51 [BE/BA News]
- Levothyroxine: A black swan? ElMaestro 2017-11-26 14:46
- Levothyroxine: A black swan? nobody 2017-11-26 16:51
- Were physicians/patients aware of the change in the formulation? Helmut 2017-11-26 17:37
- Were physicians/patients aware of the change in the formulation? nobody 2017-11-26 18:00
- Were physicians/patients aware of the change in the formulation? ElMaestro 2017-11-26 18:30
- Were physicians/patients aware of the change in the formulation? Helmut 2017-11-26 17:37
- Levothyroxine: A black swan?DavidManteigas 2017-11-27 17:53
- Levothyroxine: A black swan? Helmut 2017-11-27 20:35
- Levothyroxine: A black swan? nobody 2017-11-28 08:53